Alphatec misses Q2 estimates with $213.5M revenue, $0.07 EPS

Alphatec Holdings reported Q2 revenue of $213.5M, missing consensus of $215.5M, with EPS of $0.07 versus $0.0703 expected.

The company's earnings release did not include updated full-year guidance or management commentary on the shortfall. Alphatec, a Carlsbad, California-based spinal surgery device maker, has not yet disclosed procedure volume data for the quarter.

Revenue of $213.5M fell $1.99M short of the $215.5M consensus, a miss of 0.9 percent. EPS of $0.07 was $0.0003 below the $0.0703 estimate. Year-over-year comparisons and segment-level breakdowns were not disclosed in the release.

The narrow miss on both metrics suggests demand for spinal surgery products may be softening. Investors will watch for management's commentary on the earnings call and any revision to full-year guidance for signs of whether the shortfall reflects one-time factors or a broader demand trend.

Alphatec operates in the competitive spinal device market, where it competes with larger players including Medtronic, Globus Medical, and Zimmer Biomet. The company has focused on expanding its minimally invasive surgery portfolio and international footprint.

The earnings release did not include segment-level revenue breakdowns or regional performance data. Alphatec has not yet disclosed whether the revenue shortfall was concentrated in any particular product line or geography.

The company's next earnings call will provide an opportunity for management to address the miss and outline expectations for the remainder of fiscal 2026. Investors will be looking for clarity on procedure volume trends and any impact from competitive dynamics in the spinal surgery market.

This article is for informational purposes only and does not constitute investment advice.